

**RAIA DROGASIL S.A.**  
CNPJ/MF nº 61.585.865/0001-51  
NIRE 35.300.035.844

### **NOTICE TO SHAREHOLDERS**

**RAIA DROGASIL S.A.** (“Company” or “RD Saúde”), in continuation of the material fact disclosed on March 03 2026, informs its shareholders and the market in general that, on this date of May 04 2026, after the fulfillment of the applicable precedent conditions, including approval by the Brazilian antitrust authority CADE and by the shareholders of Grupo Profarma, the closing and completion of the transaction for the sale of 100% of 4Bio Medicamentos S.A. (“4Bio”) was carried out.

Among the closing procedures, RD Saúde received the installment of R\$ 100 million. Additionally, the Company, retains the right to receive the remaining payments, adjusted by the CDI rate, to the future credits for the active supervenience related to the ICMS tax rate differential (Difal), estimated at R\$ 120 million. The monetization will occur through the release of judicial deposits after final judgements. Lastly, the transaction will generate a corporate income tax credit estimated at R\$ 60 million.

This transaction reinforces RD Saúde’s focus on pharmaceutical retail, on greater operational efficiency and continuous improvement of results, while simultaneously strengthening the Company’s capital structure, reducing net financial expenses and incrementing its profitability and ROIC.

São Paulo, May 04, 2026.

**Flávio de Moraes Correia**  
Investor Relations Officer  
RD Saúde